Guidelines for the treatment of hypertension: A commentary

Current Therapeutic Research - Clinical and Experimental

Volumn 57, Issue 1, 1996, Pages 3-15

  Mancia, Giuseppe ^a   Mangoni, Arduino A ^b   Failla, Monica ^b   Rivolta, Maria Rosa ^b  

^a SAN GERARDO HOSPITAL   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; AMBULATORY MONITORING; BLOOD PRESSURE MONITORING; HUMAN; HYPERTENSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT SURVEY; SYSTOLIC HYPERTENSION; TARGET ORGAN; WORLD HEALTH ORGANIZATION;

EID: 0030044662     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(96)80024-5     Document Type: Article

References (51)

1. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. JAMA. 1977;237:255.
2. Cruickshank JK, Beevers DG. Ethnic and geographic differences in blood pressure. In: Bulpitt CJ. Handbook of Hypertension: Epidemiology of Hypertension. New York: Elsevier, 1985:70-88.
3. Epstein FM, Eckoff RD. The epidemiology of high blood pressure: Geographic distributions and ethiological factors. In: Stamler J, Pullman TN, Stamler R, eds. The Epidemiology of Hypertension. New York: Grune & Stratton, 1967:155.
4. The results of the Framingham Study applied to four other U.S.-based epidemiological studies of cardiovascular disease. In: Kannel WB, Gordon T, eds. The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease (Section 31). Washington, DC: U.S. Government Printing Office, DHEW 1976, Publ. No. (NIH) 76-1083.
5. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. JAMA. 1970;213:1143-1152.
6. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1993;153:154-183.
7. 1993 guidelines for the management of mild hypertension: Memorandum from a World Health Organization/International Society of Hypertension meeting. J Hypertens. 1993; 11:905-918.
8. Prichard BNC, Tuckman J. Management and mechanisms of drug treatment of hypertension. In: Genest J, Koiw E, Kuchel O, eds. Hypertension. 1977;1085-1117.
9. WHO/ISH Mild Hypertension Liaison Committee. Trials in the treatment of mild hypertension - an interim analysis. Lancet 1982;1:149.
10. Bolli P, Fernandez PG, Buhler FR. Beta-blockers in the treatment of hypertension. In: Hypertension. Pathophysiology, Diagnosis and Management. Laragh JH, Brenner B, eds. New York: Raven Press Ltd, 1990:2181-2208.
11. Laragh JH, Scaley JE. The renin-angiotensin-aldosterone system in hypertensive disorders: A key to two forms or arteriolar vasoconstriction and a possible clue to risk of vascular injury (heart attack and stroke) and prognosis. In: Hypertension. Pathophysiology, Diagnosis and Management. Laragh JH, Brenner B, eds. New York: Raven Press Ltd, 1990:1329-1348.
12. Simpson FO. Non-pharmacological approaches to the treatment of hypertension. In: Birkenhager WH, Reid JL, eds. Handbook of Hypertension. Vol. I. Clinical Aspects of Essential Hypertension. 1983:448-456.
13. Non-pharmacological approaches to the control of high blood pressure: Final report of the Subcommittee on Non-pharmacological Therapy of the 1984 Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 1986;8: 444-467.
14. The 1984 Joint National Committee. The 1984 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1984; 144:1045-1057.
15. Joint National Committee. The 1988 report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med. 1988;148: 1023-1038.
16. 1989 Guidelines for the management of mild hypertension: Memorandum from a WHO/ ISH Meeting. J Hypertens. 1989;7:689-693.
17. Report by the Management Committee. The Australian therapeutic trial in mild hypertension: Untreated mild hypertension. Lancet. 1982;1:185-191.
18. Hypertension Detection and Follow-Up Program Cooperative Group. Persistence of reduction in blood pressure and mortality of participants in the Hypertension Detection and Follow-Up Program. JAMA. 1988;259:2113-2122.
19. MRC Working Party. Stroke and coronary heart disease in mild hypertension: Risk factors and the value of treatment. BMJ. 1988;296:1565-1570.
20. Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet. 1985;1: 1349-1354.
21. Lindholm L, Ejertsson G, Schersten B. High risk of mortality in well treated male hypertensives. A retrospective study of 40-59 year-old hypertensives in a Swedish primary care district. Acta Med Scand. 1984;216:251-259.
22. Isles CG, Walker LM, Beevers DG, et al. Mortality in patients of the Glasgow Blood Pressure Clinic. J Hypertens. 1986;4:141-156.
23. Ferrari P, Rosman J, Weidmann P. Antihypertensive agents, serum lipoproteins and glucose metabolism. Am J Cardiol. 1991;67(Suppl B):26B-35B.
24. Mancia G. Treatment of hypertension and ischemic heart disease. J Cardiovasc Pharmacol. 1989;14(Suppl 9):S12-S19.
25. Mancia G. Angiotensin-converting enzyme inhibitors in the treatment of hypertension. J Cardiovasc Pharmacol. 1991;18(Suppl 7):S1-S3.
26. Parati G, Mancia G. Calcium antagonists in the treatment of arterial hypertension. Am Heart J. 1993;125(Part 2):642-648.
27. Coope J, Warrender TS. Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ. 1986;293:1145-1148.
28. Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP Hypertension). Lancet. 1991;338:1281-1285.
29. MRC Working Party. Medical Research Council trial on treatment of hypertension in older adults: Principal results. BMJ. 1992;304:405-412.
30. Kannel WB, Dawber TR, McGee DL. Prospectives on systolic hypertension: The Framingham Study. Circulation. 1980;61:1177-1182.
31. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
32. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease, part 2. Short-term reduction in blood pressure: Overview of randomized drug trials in their epidemiological context. Lancet. 1990;335:827-838.
33. Swales JD. New antihypertensive agents: Benefit of treatment. J Cardiovasc Pharmacol. 1992;20(Suppl 11):S70-S73.
34. Luscher TF, Vetter H, Siegenthaler W, Vetter W. Compliance in hypertension: Facts and concepts. J Hypertens. 1985;3(Suppl 1):3-9.
35. Pickering TG. Ambulatory blood pressure monitoring in clinical practice. Clin Cardiol. 1991;14:557-562.
36. Mancia G. Ambulatory blood pressure monitoring: Research and clinical applications. J Hypertens. 1990;8(Suppl 7):S1-S13.
37. Mancia G, Grassi G, Pomidossi G, et al. Effects of blood pressure measurement by the doctor on patient's blood pressure and heart rate. Lancet. 1983;1:695-697.
38. Mancia G, Parati G, Pomidossi G, et al. Alerting reaction and rise in blood pressure during measurement by physician and nurse. Hypertension. 1987;9:209-215.
39. Mancia G, Casadei R, Groppelli A, et al. Effects of stress on diagnosis of hypertension. Hypertension. 1991;17(Suppl 3):S56-S62.
40. SOLVD Investigators. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. NEJM. 1991;325:293-302.
41. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. NEJM. 1992;327:685-691.
42. SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. NEJM. 1992;327:669-677.
43. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. NEJM. 1991; 325:303-310.
44. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. NEJM. 1987;316:1429-1435.
45. AIRE Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-828.
46. ISIS-4 Collaborative Group. Fourth International Study of Infarct Survival: Protocol for a large simple study of the effects of oral mononitrate, of oral captopril, and of intravenous magnesium. Am J Cardiol. 1991;68(Suppl D):87D-100D.
47. GISSI-3 Group. GISSI-3 study protocol on the effects of lisinopril, of nitrates, and of their association in patients with acute myocardial infarction. Am J Cardiol. 1992;70 (Suppl C):62C-69C.
48. Mancia G, Frattola A, Trazzi S, Villani A. Clinical relevance of ambulatory blood pressure. In: Agabiti Rosei E, Mancia G, eds. Proceedings of a Workshop of the European Society of Hypertension and of the Working Group on Hypertension and the Heart of the European Society of Cardiology. High Blood Pressure. 1993;2(Suppl 1):S80-S82.
49. Zanchetti A. Antihypertensive treatment: Is blood pressure-lowering the only goal? J Cardiovasc Pharmacol. 1991;17(Suppl 4):S48-S50.
50. Dahlof B. Regression of left ventricular hypertrophy: Are there differences between antihypertensive agents? Cardiology. 1992;81:307-315.
51. Bielen EC, Fagard RH, Lijnen PJ, et al. Comparison of the effects of isradipine and lisinopril on left ventricular structure and function in essential hypertension. Am J Cardiol. 1992;69:1200-1206.